(Q34700022)

4 August 2017

European regulatory conundrum of phage therapy (English)

1 reference

4 August 2017

1 reference

Jean-Paul Pirnay

6

0 references

Mario Vaneechoutte

series ordinal

3

object named as

Mario Vaneechoutte

1 reference

4 August 2017

2

Daniel De Vos

1 reference

4 August 2017

1

Gilbert Verbeken

1 reference

4 August 2017

5

Martin Zizi

1 reference

4 August 2017

4

Maya Merabishvili

1 reference

4 August 2017

1 October 2007

1 reference

4 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

4 August 2017

2

1 reference

4 August 2017

5

1 reference

4 August 2017

485-491

1 reference

Antibacterial resistance worldwide: causes, challenges and responses

4 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

No easy way to exterminate 'superbugs' at the dawn of the third millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Do viruses form lineages across different domains of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

The origin of viruses and their possible roles in major evolutionary transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Bringing a probiotic-containing functional food to the market: microbiological, product, regulatory and labeling issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Feasibility studies to control acute diarrhoea in children by feeding fermented milk preparations Actimel and Indian Dahi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Generally recognized as safe (GRAS): history and description

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Bacteriophage penetration in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Phage therapy: the Escherichia coli experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.5.485

21 January 2018

Identifiers

DOI

10.2217/17460913.2.5.485

1 reference

4 August 2017

1 reference

PubMed ID

17927471